As FcRH5 expression is variable in myeloma (Figures 4C–4D) and anti-FcRH5/CD3 activity correlated with expression level (Figure 3C), we investigated whether patients whose tumor cells expressed low levels of FcRH5 would be predicted to respond to the anti-FcRH5/CD3 TDB. Here, FCRL5 is linked to neoplasm.